MX2012013304A - Metodo para purificar un derivado de pirrolocarbazol fusionado. - Google Patents
Metodo para purificar un derivado de pirrolocarbazol fusionado.Info
- Publication number
- MX2012013304A MX2012013304A MX2012013304A MX2012013304A MX2012013304A MX 2012013304 A MX2012013304 A MX 2012013304A MX 2012013304 A MX2012013304 A MX 2012013304A MX 2012013304 A MX2012013304 A MX 2012013304A MX 2012013304 A MX2012013304 A MX 2012013304A
- Authority
- MX
- Mexico
- Prior art keywords
- purifying
- fused pyrrolocarbazole
- pyrrolocarbazole derivative
- derivative
- relates
- Prior art date
Links
- QNMMYUBZGLXCCK-UHFFFAOYSA-N pyrrolo[3,2-a]carbazole Chemical class N1=C2C=CC=CC2=C2C1=C1C=CN=C1C=C2 QNMMYUBZGLXCCK-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 2
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 abstract 1
- -1 pyrrolocarbazole compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34583110P | 2010-05-18 | 2010-05-18 | |
| PCT/US2011/036814 WO2011146488A1 (en) | 2010-05-18 | 2011-05-17 | Method for purifying a fused pyrrolocarbazole derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012013304A true MX2012013304A (es) | 2013-04-03 |
Family
ID=44168420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013304A MX2012013304A (es) | 2010-05-18 | 2011-05-17 | Metodo para purificar un derivado de pirrolocarbazol fusionado. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8884014B2 (enExample) |
| EP (1) | EP2571885B1 (enExample) |
| JP (2) | JP5828594B2 (enExample) |
| KR (1) | KR101815332B1 (enExample) |
| CN (1) | CN102958934B (enExample) |
| AU (1) | AU2011256264B2 (enExample) |
| BR (1) | BR112012029374B1 (enExample) |
| CA (1) | CA2799517C (enExample) |
| CL (1) | CL2012003208A1 (enExample) |
| EA (1) | EA021869B1 (enExample) |
| ES (1) | ES2530015T3 (enExample) |
| IL (2) | IL223016A0 (enExample) |
| MX (1) | MX2012013304A (enExample) |
| MY (1) | MY156830A (enExample) |
| NZ (1) | NZ604135A (enExample) |
| PH (1) | PH12012502250A1 (enExample) |
| SG (2) | SG185645A1 (enExample) |
| UA (1) | UA108498C2 (enExample) |
| WO (1) | WO2011146488A1 (enExample) |
| ZA (1) | ZA201209305B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074374A1 (es) | 2008-11-19 | 2011-01-12 | Cephalon Inc | Formas de un compuesto de pirrolocarbazol fusionado, composiciones que las comprenden y su uso en el tratamiento de la angiogénesis y los tumores sólidos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200401316T4 (tr) * | 2000-09-29 | 2004-07-21 | Eli Lilly And Company | Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler |
| US7169802B2 (en) * | 2003-12-23 | 2007-01-30 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| JP2006241579A (ja) | 2005-03-07 | 2006-09-14 | Nippon Paint Co Ltd | 化成処理剤及び表面処理金属 |
| AR074374A1 (es) | 2008-11-19 | 2011-01-12 | Cephalon Inc | Formas de un compuesto de pirrolocarbazol fusionado, composiciones que las comprenden y su uso en el tratamiento de la angiogénesis y los tumores sólidos. |
-
2011
- 2011-05-17 JP JP2013511294A patent/JP5828594B2/ja active Active
- 2011-05-17 MX MX2012013304A patent/MX2012013304A/es active IP Right Grant
- 2011-05-17 KR KR1020127032917A patent/KR101815332B1/ko active Active
- 2011-05-17 AU AU2011256264A patent/AU2011256264B2/en active Active
- 2011-05-17 CA CA2799517A patent/CA2799517C/en active Active
- 2011-05-17 NZ NZ604135A patent/NZ604135A/en unknown
- 2011-05-17 SG SG2012084851A patent/SG185645A1/en unknown
- 2011-05-17 BR BR112012029374-5A patent/BR112012029374B1/pt active IP Right Grant
- 2011-05-17 PH PH1/2012/502250A patent/PH12012502250A1/en unknown
- 2011-05-17 MY MYPI2012004977A patent/MY156830A/en unknown
- 2011-05-17 CN CN201180024787.XA patent/CN102958934B/zh active Active
- 2011-05-17 SG SG10201503541WA patent/SG10201503541WA/en unknown
- 2011-05-17 UA UAA201214484A patent/UA108498C2/ru unknown
- 2011-05-17 EP EP11721691.1A patent/EP2571885B1/en active Active
- 2011-05-17 EA EA201291269A patent/EA021869B1/ru not_active IP Right Cessation
- 2011-05-17 ES ES11721691.1T patent/ES2530015T3/es active Active
- 2011-05-17 WO PCT/US2011/036814 patent/WO2011146488A1/en not_active Ceased
-
2012
- 2012-11-13 IL IL223016A patent/IL223016A0/en active IP Right Grant
- 2012-11-16 CL CL2012003208A patent/CL2012003208A1/es unknown
- 2012-11-16 US US13/678,886 patent/US8884014B2/en active Active
- 2012-12-07 ZA ZA2012/09305A patent/ZA201209305B/en unknown
-
2015
- 2015-10-19 JP JP2015205469A patent/JP2016074668A/ja active Pending
- 2015-10-22 IL IL242221A patent/IL242221B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012006180A2 (pt) | processos e intermediários para a preparação de análogos de 1'-substituido carba-nucleosídeo | |
| MX347257B (es) | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. | |
| EP2608669A4 (en) | NEW PYRAZOLO- [1,5-A-] PYRIMIDINE DERIVATIVES AS ANTI-MTOR HEMMER | |
| EP3778606A3 (en) | Condensed imidazolylimidazoles as antiviral compounds | |
| ZA201306719B (en) | 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
| MX358682B (es) | Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). | |
| AU2013380573A8 (en) | A process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane | |
| WO2012025944A3 (en) | Sitagliptin, salts and polymorphs thereof | |
| IL229993A0 (en) | A process for the preparation of 8-Alkoxy[1,2,4]triazolo[5,1-c]pyrimidine-2 amines 5-converted | |
| PL2531505T3 (pl) | Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami | |
| UY33325A (es) | Purificación mediante adsorción de colorante caramelo | |
| HK1203501A1 (en) | 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4]nonane- 6 -one compound as voltage-gated sodium channels modulator | |
| IN2014KN02722A (enExample) | ||
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| WO2011095571A3 (de) | Verfahren zur herstellung von astaxanthin-dimethyldisuccinat | |
| TN2015000008A1 (en) | Method for preparing substituted triazolopyridines | |
| PH12014501327A1 (en) | Processes for making magnolol analogs | |
| MY183980A (en) | Commercial scale process for production of prrsv | |
| WO2010097802A3 (en) | A process for the preparation of etoricoxib | |
| PH12012502250A1 (en) | Method for purifying a fused pyrrolocarbazole derivative | |
| WO2013072938A3 (en) | Process for the preparation of roflumilast | |
| MX2014000828A (es) | Compuestos de pirazol[3,4-d]pirimidina, su preparación y su uso como ligandos sigma. | |
| NZ711328A (en) | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane | |
| PL2004670T3 (pl) | Sposób wytwarzania pochodnych lysobactin | |
| MX2014012822A (es) | Proceso para elaborar derivados de naftiridina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: CEPHALON, INC.* |
|
| FG | Grant or registration |